Why Investors Shouldn't Freak Out Over Vertex's Latest Trial Results
Results of a small study of what could become the third cystic fibrosis drug to come out of Vertex Pharmaceuticals showed the drug worked about as well as the Boston biotech’s second potential drug, approval of which is expected this spring. But investors were apparently hoping for more.
Vertex (Nasdaq: VRTX) reported the results of a 39-patient mid-stage study of the drug known as VX-661 this morning.
Help employers find you! Check out all the jobs and post your resume.
Vertex (Nasdaq: VRTX) reported the results of a 39-patient mid-stage study of the drug known as VX-661 this morning.
Help employers find you! Check out all the jobs and post your resume.